Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q1 2025 · 10-Q
Revenue$0.00$0.00— vs Q1 2024 Net Income-$10.30K-$10.30KN/M vs Q1 2024 EPS Diluted$0.00$0.00— vs Q1 2024 Operating Income-$8,934N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed Jul 24, 2025 · 115 d after period end